VTVivianne Lily Tawfik

Vivianne Lily Tawfik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vivianne Lily Tawfik has a total of 247 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ethological profiling defines pain behaviors and parses analgesia from drug side effects in a mouse model of complex regional pain syndrome

    by Gabriella P.B. Muwanga, Anahis C. Tena, Amanda Pang, Sedona N. Ewbank, Janelle Siliezar-Doyle, Amy R. Nippert, Raag D. Airan, Vivianne L. Tawfik

    Complex regional pain syndrome (CRPS) is a form of chronic postinjury pain affecting the extremities with contributions from the somatic and sympathetic nervous systems. The mouse tibial fracture-cast model was developed to enable preclinical study of CRPS mechanisms and guide condition-specific drug development. Given the inherent limitations of reflex pain measures in mice, we sought to holistically characterize pain-like behaviors in this model in neutral and aversive environments using quantitative behavior analysis with LabGym, a user-friendly automation tool that requires no special equipment or extensive computational resources. This study shows that tibial fracture-cast injury causes distinct changes in naturalistic and nocifensive behaviors in male and female mice in neutral and aversive environments, demonstrating reliable behavioral categorization using robust learning-based holistic assessment. As proof-of-concept for therapeutic testing, we leveraged this behavioral evaluation to characterize the peripheral vs central effects of targeting alpha-2 receptors (α2-AR) with dexmedetomidine (DEX), a selective α2-AR agonist with analgesic, sedative, and anxiolytic properties. We found that DEX reduced mechanical allodynia primarily through central α2-ARs. Dexmedetomidine also decreased motion metrics, grooming, and rearing in an open field and distinctly affected the quality and quantity of grooming in an aversive environment, and systemic α2-AR antagonists did not suppress this effect. Importantly, we also determined that the sedative effects of DEX were attenuated in injured compared with uninjured mice, consistent with known sympathetic nervous system activation in CRPS. Overall, this study highlights the use of automated behavioral testing to parse analgesia from sedation in a unique preclinical pain model.


  • Open Access

    Translatome profiling of spinal cord astrocytes reveals distinct gene signatures associated with acute and chronic pain

    by Janelle Siliezar-Doyle, Richard K. Perez, Emma Stauffenberg, Amy R. Nippert, Vivianne L. Tawfik


  • Open Access

    Library docking for Cannabinoid-2 Receptor ligands

    by Moira M. Rachman, Christos Iliopoulos-Tsoutsouvas, Michael Dominic Sacco, Xinyu Xu, Cheng-Guo Wu, Emma Santos, Isabella S. Glenn, Lu Paris, Michelle K. Cahill, Suthakar Ganapathy, et al.

    Cannabinoid receptors are therapeutically promising GPCRs that are also interesting test systems for structure-based methods, which have targeted them previously. Here we used the CB2 receptor as a template to explore several topical questions in library docking. Whereas an earlier campaign against the CB1 receptor led to potent but relatively non-selective ligands, here we found that targeting interactions with polar, orthosteric site residues led to subtype-selective ligands. Docking hit rate and especially hit affinity improved in moving from a 7 million to a 2.6 billion molecule library. Similar to earlier studies, docking against active and inactive states of the receptor did not reliably bias toward the discovery of agonists or inverse agonists. Cryo-EM structures of two of the new agonists, each in a different chemotype, superposed well on the docking predictions. Correspondingly, structure-based optimization led to 10- to 140-fold improvements within three different series, also consistent with well-behaved ligand families. Hit rates with a fully enumerated 2.6 billion molecule library resembled those of an implied 11 billion molecule library from a building-block method, consistent with the latter’s ability to explore this space, though higher affinities were discovered from the fully enumerated set. Overall, eight diverse families of ligands, with potencies <100 nM and mostly unrelated to previously known ligands were found. Implications for future studies are considered.

  • Top Cited Papers
    Open Access

    No evidence of immediate or persistent analgesic effect from a single dose of psilocybin in three mouse models of pain

    by Nicholas S. Gregory, Tyler E. Girard, Akila Ram, Austen B. Casey, Robert C. Malenka, Vivianne L. Tawfik, Boris D. Heifets

    The psychedelic psilocybin may have lasting therapeutic effects for patients with chronic pain syndromes. Some preclinical data suggest these putative benefits derive from direct analgesic effects; however, this possibility has not been comprehensively tested in preclinical models. Here, we evaluated the analgesic properties of a single exposure to psilocybin at acute and chronic time points in Complete Freund’s Adjuvant-induced inflammatory pain, spared nerve injury model of neuropathic pain, and acid-induced muscle pain. Across these models, we tested a range of doses (0.3, 2, and 10 mg/kg i.p.) in male and female mice using multiple behavioral assays evaluating sensory aspects (von Frey, cold plate, Hargreaves, thermal place preference, and muscle withdrawal threshold) and functional aspects of pain (marble burying). We further tested the effects of psilocybin on the affective dimension of pain in a surgical model of acute pain (mouse grimace scale). Except for cold sensitivity, we found no effect of psilocybin across pain models, behavioral assays, drug doses, or sex. The apparent reduction in cold sensitivity may be explained by profound hypothermia induced by psilocybin rather than true analgesia.


  • Open Access

    Psilocybin has no immediate or persistent analgesic effect in acute and chronic mouse pain models

    by Nicholas S. Gregory, Tyler E. Girard, Akila Ram, Austen B. Casey, Robert C. Malenka, Vivianne L. Tawfik, Boris Dov Heifets

    The psychedelic psilocybin may have lasting therapeutic effects for patients with chronic pain syndromes. Some clinical and preclinical data suggest these putative benefits derive from direct analgesic effects. However, this possibility has not been comprehensively tested in preclinical models. Here, we show that psilocybin is not analgesic over a range of doses across multiple pain assays and models of acute and chronic inflammatory, neuropathic, or musculoskeletal pain in mice.


  • Open Access

    Aging and injury drive neuronal senescence in the dorsal root ganglia

    by Lauren J. Donovan, Chelsie L. Brewer, Sabrina F. Bond, Alexander M. Laslavic, Aleishai Pena Lopez, Laura Colman, Claire E. Jordan, Linus H. Hansen, Oscar C. González, Akshay Pujari, et al.

    Aging negatively impacts central nervous system function; however, there is limited information about the cellular impact of aging on peripheral nervous system function. Importantly, injury to vulnerable peripheral axons of dorsal root ganglion (DRG) neurons results in somatosensory dysfunction, such as pain, at higher rates in aged individuals. Cellular senescence is common to both aging and injury and contributes to the aged pro-inflammatory environment. We discovered DRG neuron senescence in the context of aging and pain-inducing peripheral nerve injury in young (~3 months) and aged (~24 months) male and female mice. Senescent neurons were dynamic and heterogeneous in their expression of multiple senescence markers, including pro-inflammatory factor IL6. Senescence marker-expressing neurons had nociceptor-like profiles, included high-firing phenotypes and displayed increased excitability after IL6 application. Furthermore, elimination of senescent cells resulted in improvement of nociceptive behaviors in nerve-injured mice. Finally, male and female post-mortem human DRG contained senescent neurons that increased with age (~32 years old versus 65 years old). Overall, we describe a susceptibility of the peripheral nervous system to neuronal senescence—a potential targetable mechanism to treat sensory dysfunction, such as chronic pain, particularly in aged populations.


  • Open Access

    Ethological profiling of pain and analgesia in a mouse model of complex regional pain syndrome

    by Gabriella P. B. Muwanga, Amanda Pang, Sedona N. Ewbank, Janelle Siliezar-Doyle, Amy R. Nippert, Raag D. Airan, Vivianne L. Tawfik

    Complex regional pain syndrome (CRPS) is a form of chronic post-injury pain affecting the extremities. The mouse tibial fracture- cast model was developed to enable preclinical study of CRPS mechanisms and guide condition-specific drug development. Given the inherent limitations of reflex pain measures in mice, we sought to characterize pain-like behaviors in this model more holistically. We evaluated spontaneous and evoked pain and naturalistic behaviors after tibial fracture-cast injury in male mice in neutral and aversive environments using LabGym. Here, we report a unique ethological signature of pain in injured mice characterized by reflexive allodynia, thermal hyperalgesia, frequent grooming and reduced rearing in neutral and aversive environments, and decreased paw withdrawal and increased paw licking in an aversive environment. As proof-of-concept, we also leveraged this holistic behavioral evaluation for drug screening by characterizing the peripheral versus central effects of targeting alpha-2 receptors (α2-AR) in the tibial fracture-cast model. We evaluated the impact of systemic delivery of dexmedetomidine (DEX), a selective α2-AR agonist, with or without antagonists, on holistic behavioral metrics in injured male mice. We found that DEX reduced mechanical allodynia primarily via central α2-ARs. DEX also decreased motion metrics, grooming and rearing in an open field, and distinctly affected the quality and quantity of grooming in an aversive environment, and this effect was not suppressed by systemic α2-AR antagonists. Ultimately, this study holistically captures pain-related behaviors and provides a detailed characterization of the relative contributions of peripheral and central α2-ARs to alpha2-mediated analgesia in male mice after tibial fracture-cast injury.

  • Open Access

    Comprehensive overview of the anesthesiology research landscape: A machine Learning Analysis of 737 NIH-funded anesthesiology primary Investigator's publication trends

    by Marc Ghanem, Camilo Espinosa, Philip Chung, Momsen Reincke, Natasha Harrison, Thanaphong Phongpreecha, Sayane Shome, Geetha Saarunya, Eloise Berson, Tomin James, et al.


  • Astrocytes: Dual Roles in Chronic Pain and Memory Formation

    by Vivianne L. Tawfik

    Astrocytes are glial cells, abundant in the central nervous system, that form a highly interconnected and organized network of cells.1 They make simultaneous close contact with thousands of synapses, allowing them to rapidly respond to, and even orchestrate, neuronal activity in homeostatic and pathologic conditions.2 It is now clear, however, that the specific contribution of astrocytes is location- and context-specific. For example, in the spinal cord, astrocytes can become “activated” after pain-producing injuries and negatively contribute to increased neuronal excitability through the release of gliotransmitters such as adenosine triphosphate, D-serine, and L-lactate.3,4 These complex cells are also, however, key positive contributors to processes such as memory formation.5 Astrocytes in the CA1 region of the hippocampus release L-lactate, which is taken up by neurons and triggers a series of downstream synaptic structural changes requisite for long-term memory.6In this issue, Han et al.7 perform a series of elegant experiments providing a unifying view of how astrocytes in the hippocampus contribute to memory deficits after pain-producing neuropathic injury in mice and rats. In the first part of the paper, the authors demonstrate poor short-term spatial memory and reduced excitability of pyramidal neurons in CA1 of the hippocampus after spared nerve injury, confirming comorbid pain and memory deficits, similar to human studies.8 Coincident with this memory impairment, L-lactate levels and calcium responses from astrocytes were also suppressed. Importantly, infusion of L-lactate into the CA1 region attenuated pain behaviors and improved memory deficits, while inhibiting lactate synthesis in astrocytes, or transport into neurons, induced paw sensitivity in naïve mice. While these experiments provided evidence connecting L-lactate to pain and memory deficits, the contributory role of astrocytes remained unclear. The authors thus took advantage of a highly novel and specific approach to modulate astrocytes only in the CA1 region: viral-based Designer Receptors Exclusively Activated by Designer Drugs (DREADDs). DREADDs are recently developed tool G-protein–coupled receptors linked to excitatory or inhibitory G proteins, often referred to as “chemogenetics.”9 DREADDs are solely agonized by the drug clozapine-N-oxide, allowing for the specific activation or suppression of G-protein–coupled receptor–mediated signaling in the target cell. When paired with viruses with tropism for specific cell types (for example, AAV2/8 for astrocytes) that include cell-type specific promoters (such as GfaABC1D for astrocytes), the result is the ability to express DREADDs with high temporal and spatial control. Using DREADD-containing viruses with astrocyte promoters injected into the CA1 region, the authors demonstrate that activation of astrocytes increased hippocampal L-lactate and CA1 neuronal firing, improved pain-like behaviors, and reversed the spared nerve injury–induced memory deficit. In contrast, chemogenetic inhibition of astrocytes in naïve rodents caused pain-like behaviors and memory impairment. Together these experiments nicely demonstrate that CA1 astrocytes, and their L-lactate release, are both necessary and sufficient for pain modulation and memory formation.The contribution of astrocytic L-lactate to memory formation is not a new concept, but rather has been demonstrated by several groups during the past decade.5,6,10 One discrepancy between previous work and the current study is that inhibition of astrocytic L-lactate production or release or uptake in CA1 has previously been linked only to long-term, and not short-term, memory formation.6 Han et al. utilize just one assay for memory, novel object recognition, which is a test for short-term spatial memory, and demonstrate that astrocytic L-lactate directly affects this outcome. One intriguing possibility for this contradictory finding is that in the context of pain-producing injury, astrocyte L-lactate may have expanded functions. The addition of tests to assay long-term memory in the context of pain would further solidify this prospect.In the second part of the article, Han et al. expand their studies to the locus coeruleus, the origin of noradrenaline-releasing fibers projecting to the hippocampus, among other areas of the brain. The authors demonstrate that activation of locus coeruleus neurons using a viral DREADD approach, or the administration of a β2-adrenergic agonist, lead to decreased pain-like behaviors, improved memory deficits, and enhancement of astrocytic L-lactate release in CA1. What remains unclear is how β2-adrenergic receptor activation leads to L-lactate release from astrocytes, especially given that recent transcriptome profiling of astrocytes fails to identify the transcript for this receptor in hippocampal astrocytes,11,12 and there is variability in the immunostaining presented in the current article. It is therefore possible that locus coeruleus–derived noradrenaline release in the hippocampus acts on local neurons, which definitively express the β2-adrenergic receptor, and that the effect on astrocytes is indirect, through a change in neuronal excitability.The most novel aspect of the current work by Han et al. is the connection to chronic pain, a condition that anesthesiologists are uniquely positioned to diagnose and treat. Astrocytes may in fact have a dual function in the case of chronic pain: in the spinal cord, their activation increases pain behaviors through the release of algesic mediators, while in the hippocampus, their activation enhances memory formation through the release of L-lactate. This suggests that astrocytes may both influence and respond to the excitability state of neurons in their direct environment. For example, it is possible that primary afferent neuron hyperexcitability, triggered by pain-producing...